
Osteoarthritis
Celecoxib and naproxen beneficial in Asian patients with knee OA compared to a placebo
Int J Rheum Dis. 2016 Mar;19(3):262-70367 patients of Asian descent with knee osteoarthritis were randomized to receive 6 weeks of treatment with either once daily celecoxib (200mg), twice daily naproxen (500mg), or placebo. The study was conducted in order to determine the effect of nonsteroidal anti-inflammatory drugs in an Asian population when treating the symptoms of osteoarthritis. Findings indicated that patients' assessment of arthritis pain was improved with celecoxib, naproxen, and placebo treatment at 6 weeks, however, between-group differences were insignificant. In the physicians' and patients' global assessment of arthritis, the active treatments were superior to placebo, however, differences between active treatment groups were insignificant. Celecoxib treatment yielded significantly greater WOMAC total, pain, and physical function scores in comparison to a placebo. While differences did exist between naproxen and the placebo, these differences were not significant. Treatment-related adverse events were comparable between all three groups.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.